ABSI Nasdaq Earnings call
Absci Corp (ABSI) · Q2 2026 results
Share price: $10.12 · 2026-11-11
Results Q2 2026 vs Q1 2026 · previous quarter · published 11 Aug 2026 and 7 May 2026
Net loss widened on the previous quarter. Management sounded restrained, in its script and in answers to analysts.
Only a basic analysis is available for this company at the moment.
1 · Numbers
Loss widened
Net income vs Q1 2026
Outlook given
Net income -33.2M vs -29.6M
Revenue +47.9%
Net income -33.2M vs -30.6M in Q2 2025 and -29.6M last quarter.
2 · How management spoke
Restrained
Less upbeat than 70% of company calls
Answers to analysts: cautious, in line with the script.
Similar to last call.
3 · What stood out
Figure
The company estimates a potential total available market greater than $25 billion in the U.S. based on its market research.
Valuation
Reverse DCF. Free cash flow from the last full fiscal year, grown for 10 years, discounted back, plus a terminal value. “Implied growth” is the rate the current price assumes.
Valuation unavailable: free cash flow and profit were negative in the last full year and on average over the last three, so there is nothing to discount.
Current price
$10.12
close of 2026-11-11
Revenue growth, 3 years
−14.8% a year
compound annual rate (CAGR)
Free cash flow 2023
−$0.1B
Free cash flow 2024
−$0.1B
Free cash flow 2025
−$0.1B
Read between the lines
-
Guidance
Instead of a targeted dosing interval, the therapy is being framed around durability and infrequent dosing as a new category.
Source quote
“The takeaway is that the profile of ABS-201 would establish a brand-new category of therapy based on durability, infrequent dosing... As you know, we conducted sizable consumer surveys and surveys with dermatologists. When we test a profile with efficacy consistent with at least some reports of high-dose oral minoxidil—around 35 hairs per cm² in target area hair count—we see massive potential for adoption, and that is how we get to a potential $25 billion TAM on a TPP that looks like that.”
Tone
How upbeat the language was, compared with other companiesiTone counts positive minus negative finance words, adjusted for length. Executives mostly speak positively, so the labels compare each call with every company's latest call: “typical” is the middle third, “very upbeat” the top tenth, “cautious” the bottom tenth.. Dot: Q2 2026. Ring: Q1 2026.
Script and answers carried a similar tone, so the script's message held up under questioning.
Sentences that drove the tone
“A directionally positive signal of hair growth at 13 weeks would give us even further confidence in seeing more robust hair growth at 26 weeks and beyond, as is supported...”
“As a reminder, our consumer research survey as well as input from leading KOLs inform our view that a 26 week increase in target area hair count of 30 to...”
“We believe a target area hair count result above that level would expand the market further and that a less robust result would still unlock a multibillion dollar market opportunity.”
Full figures
USD · SEC EDGAR XBRL (10-Q, period end 2026-06-30)
| Metric | Q2 2026period end 2026-06-30 | Q1 2026period end 2026-03-31 | Change | Q2 2025 | YoY |
|---|---|---|---|---|---|
| Revenue | 318.0K | 215.0K | +47.9% | 593.0K | −46.4% |
| Operating income | -34.2M | -30.8M | Loss widened | -31.4M | Loss widened |
| Net income | -33.2M | -29.6M | Loss widened | -30.6M | Loss widened |
| EPS | -0.21 | -0.19 | Loss widened | -0.24 | Loss narrowed |
| P/E | 12-mo loss | 12-mo loss | — | 12-mo loss | — |
Topics
Most discussed now
- Absci's partnership with Eli Lilly is tailored around the clinical development strategy for ABS-201.
- New Absci sees a huge opportunity to capitalize on the interest in Total Vitality combined with consumer shift towards more direct...
- A plan to engage with the FDA regarding development strategy Absci's partnership with Eli Lilly including anticipated benefits thereof in...
- Absci is also advancing a preclinical pipeline focused on immunological and inflammatory indications that fit into its broader strategy…
- Absci is also actively exploring other potential underserved indications for which prolactin receptor inhibition could offer a…
Faded since Q1 2026
- Fading Absci plans to share an interim POC readout, including 13-week hair regrowth data, in the second half of this year.
- Fading Certain research findings discussed today reflect participant responses to a hypothetical product profile and do not represent clinical...
- Fading Certain statements may also include projections regarding potential market opportunity.
- Fading From the preliminary half-life and PK, Absci is feeling very optimistic and look forward to sharing the full data in...
Latest announcements
Official filings, newest first.
- Results of operations; Other events · SEC 8-K
- Material agreement; Other events · SEC 8-K
- Other events · SEC 8-K
- Shareholder vote results · SEC 8-K
- Results of operations; Other events · SEC 8-K
- Results of operations; Other events · SEC 8-K
- Material agreement; Director or officer change; Regulation FD disclosure · SEC 8-K
- Other events · SEC 8-K